NCT03537833: IPPEM

Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed

Completed Last updated 14 February 2022

What this trial tests

trial testing pemetrexed-related hematological toxicity in Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy in 172 participants. Completed in 11 February 2022.

Timeline

2 May 2018

Primary endpoint
18 February 2021

11 February 2022

Quick facts

Lead sponsor	CHU de Reims
Status	Completed
Study type	OBSERVATIONAL
Enrollment	172
Start date	2 May 2018
Primary completion	18 February 2021
Estimated completion	11 February 2022
Sites	1 location across France

Drugs / interventions tested

• pemetrexed-related hematological toxicity

Conditions studied

• Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy — all drugs for Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy →

Sponsor

CHU de Reims — full company profile →

Who can join

18 and older, any sex, with Patients With Non-small Cell Lung Cancer (NSCLC) and Pleural Mesothelioma and Treated With a Pemetrexed-based Chemotherapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pemetrexed is a multi-folate inhibitor approved in the treatment of non-small cell lung cancer (NSCLC) and pleural mesothelioma. Its toxicity profile is mainly hematologic (anemia, neutropenia and thrombopenia) and can be limiting when \> grade 2 according to NCI-CTCAE criteria. First clinical trials highlighted hematologic toxicity, especially anemia, which was reduced by decreasing pemetrexed dosage from 600 to 500 mg/m² Q3W and by adding systematic vitamin supplementation (B9/B12). Despite this, incidence of hematological toxicity remains frequent with anemia occurring in more than 20% of patients treated by pemetrexed in combination. Methotrexate, a well-known antineoplastic drugs used in several cancer and non-cancer disease conditions can also induced severe hematologic toxicity in case of methotrexate-reduced elimination and, as a consequence, its accumulation. For example, the elimination of methotrexate is mediated by tubular secretion through type 1 and type 3 organic anion transport (hOAT1 and hOAT3). Association with drugs that inhibits hOATs can induced a hematological toxicity caused by methotrexate accumulation. Among these, proton pump inhibitors (PPIs) are known to inhibit hOATs. The drug interaction that results from their combination with methotrexate is clinically relevant and lead to an increased hematological toxicity. However, hypothetical drug interaction between PPIs and pemetrexed is unknown while pemetrexed seems to be mostly eliminated by hOAT3 (11-fold higher than methotrexate). One study revealed lansoprazole to inhibits in vitro hOAT3. This same study investigates in a retrospective chart patients treated by pemetrexed and the study found a significant association between combination with PPI and hematological toxicity by pemetrexed. Unfortunately this study lacks of relevant methodology and suffered from its retrospective chart. This potential drug interaction must be a real concern for oncologists and clinical pharmacists. The investigators aim to investigate the potential association between PPIs and pemetrexed combination and the incidence of hematological toxicity in a multicenter and prospective study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
   Slimano F, Le Bozec A, Cransac A, Foucher P, et al · · 2022 · cited 7× · PMID 35263663 · DOI 10.1016/j.lungcan.2022.02.007